Why defensible workplace testing depends on laboratory confirmation, qualified collection, split specimens, and Medical Review Officer oversight
The bottom line: A point-of-collection device can produce a preliminary result. It cannot supply the complete safeguards needed before an employer withdraws an offer, removes an employee from duty, disciplines, or terminates someone.
Instant urine and oral-fluid devices are attractive because they are fast, inexpensive, and easy to purchase. A recent distributor article explains labels such as “CLIA waived,” “510(k) cleared,” and “Employment & Insurance” and suggests that several categories are well suited to workplace decisions. Those labels matter—but they do not answer the question an employer must ask: Is the entire testing process reliable, fair, lawful, and strong enough to support an adverse personnel decision?
Liability risk is not limited to non-negative screens. Treating a point-of-collection device negative result as conclusive may create a false sense of security: a false negative can leave prohibited drug use undetected and, if a later workplace incident occurs, expose the employer to allegations that it relied on an unreliable preliminary device or failed to follow the manufacturer’s instructions and obtain certified-laboratory testing.
The safer answer is to treat every onsite non-negative as presumptive. Preserve the specimen, send it to a properly certified laboratory for confirmation, and wait for review by a qualified Medical Review Officer (MRO) before acting. The Department of Transportation (DOT) requires this kind of system for regulated testing. Non-DOT employers should strongly consider comparable safeguards in a completely separate program, adjusted for applicable state and local law.
Product classifications are not decision-making standards. #
The U.S. Food and Drug Administration (FDA) explains that a 510(k) submission generally demonstrates substantial equivalence to a legally marketed device. A CLIA waiver addresses the complexity of a clinical test and the type of laboratory certificate under which it may be performed. Neither designation certifies the employer’s collection procedure, chain of custody, confirmation method, MRO process, policy language, or compliance with employment law.
The distinction is even more important for products labeled solely for Employment & Insurance testing. FDA states that it does not review those drugs-of-abuse tests when their labeling limits them to employment and insurance use and excludes federal testing programs. Therefore, an E&I label should not be presented—or understood—as proof that FDA reviewed the product to the same standard as a 510(k) submission. It describes intended use; it does not validate an employer’s final decision.
FDA’s own consumer guidance also calls rapid positive results “preliminary” or “presumptive,” says laboratory tests are the most reliable way to confirm them, and warns against serious action before laboratory confirmation. That caution is even more compelling when a person’s job and reputation are at stake.
What the DOT model adds—and why each safeguard matters. #
Certified laboratory analysis. Under 49 CFR Part 40, only specimens screened and confirmed at laboratories certified by the U.S. Department of Health and Human Services may be used for DOT drug testing. Point-of-collection urine tests, point-of-collection oral-fluid tests, and other instant drug tests are not authorized. A certified laboratory uses documented chain-of-custody controls, validated initial and confirmation methods, specified cutoffs, specimen-validity procedures, quality controls, and trained scientific personnel. The confirmation test is more specific than a rapid immunoassay screen and identifies the particular drug or metabolite. Part 40 authorizes laboratory-based urine and oral fluid testing, but DOT oral fluid implementation requires at least two HHS-certified oral fluid laboratories; employers must verify current availability before using that option.
Qualified collectors. A reliable test begins before the specimen reaches the laboratory. DOT-qualified collectors must be trained in correct form completion, specimen security, privacy, tampering attempts, insufficient specimens, temperature problems, fatal and correctable flaws, and chain of custody. They must also demonstrate proficiency through error-free mock collections. For a non-DOT program, using collectors trained to comparable standards reduces identification errors, contamination, broken seals, undocumented transfers, canceled tests, and avoidable confrontations.
Split specimens. A split collection divides one specimen into a primary Bottle A and a separately sealed Bottle B while the donor is present. If the MRO verifies a positive, adulterated, or substituted DOT result, the employee may request testing of the unopened split at a second certified laboratory. This is a meaningful safeguard against specimen mix-ups, analytical error, and disputes. Retesting leftover urine from an instant-test cup is not the same protection: the material may have been opened, handled, consumed by the device, or left without an independently sealed and documented second specimen.
Medical Review Officer review. An MRO is a licensed physician with specialized qualification training who acts as an independent, impartial gatekeeper. The MRO reviews the custody-and-control documentation, interviews the employee after a laboratory-confirmed non-negative result, and determines whether a legitimate medical explanation exists. A confirmed laboratory finding for an opioid or amphetamine, for example, is not automatically proof of illegal drug use. A lawful prescription may explain the result. Human resources should not attempt this medical verification itself.
These safeguards protect the employer, too. #
A disciplined process does more than protect employees. It gives management a clear, consistent basis for action and creates evidence that can withstand an unemployment claim, grievance, agency audit or inquiry, arbitration, or lawsuit. It also helps protect confidential prescription and disability-related information. The Equal Employment Opportunity Commission advises employers to give a tested person an opportunity to explain lawful medication use that may account for a drug-test result. An MRO can evaluate that explanation and ordinarily report the verified workplace result without disclosing unnecessary diagnosis or prescription details to management.
The alternative—allowing a supervisor or office employee to read a test cup, ask about medications, and make an immediate decision—creates multiple points of risk. The screen may cross-react with a medication; the wrong cutoff may be used; the device may have been stored improperly or read outside its time window; the donor may be misidentified; chain of custody may be incomplete; and confidential medical information may be collected or shared unnecessarily.
A practical rule for non-DOT programs. #
Employers that choose rapid devices for non-DOT testing should use them only as preliminary screens within a written program. A non-negative should trigger secure sealing and documented shipment to a certified laboratory—not discipline. Final action should wait for laboratory confirmation and MRO verification. Whenever feasible, collect a true split specimen at the outset and use a collector trained to DOT-comparable standards.
The non-DOT program must remain separate from the DOT program: separate policy, forms, account setup, specimen records, and results. Part 40 expressly requires DOT and non-DOT tests to be separate and prohibits using the federal Custody and Control Form for a non-DOT test. Employers must also review state and local law, collective-bargaining obligations, privacy rules, marijuana protections, and any industry-specific requirements before adopting or changing a program.
Before relying on a test result, ask five questions: Was the specimen collected by a competent collector under a documented chain of custody? Was an independently sealed split preserved? Did an appropriately certified laboratory perform confirmation testing? Did a qualified MRO verify the result? Does the contemplated action comply with the written policy and applicable law?
If any answer is “no,” pause before making an adverse decision. The minutes saved by an instant result are rarely worth the cost of a preventable error. A workplace drug-testing program is defensible because of the integrity of the entire process—not because a product package carries a particular acronym.
Official references and further reading #
49 CFR Part 40 — Current federal procedures for transportation workplace drug and alcohol testing
DOT § 40.210 — Only laboratory-screened and confirmed urine or oral fluid is authorized; POC and instant drug tests are not
FDA — Drugs of Abuse Tests—including FDA’s statement concerning Employment & Insurance devices
FDA — Drugs of Abuse Home Use Test—preliminary results and laboratory confirmation
FDA — CLIA Waiver by Application—what a CLIA waiver means
EEOC — Lawful opioid use, drug testing, and the opportunity to provide an explanation
DOT — HHS-certified oral-fluid laboratories and the two-laboratory implementation condition
Editorial note: This article provides general educational information, not legal advice. Non-DOT testing requirements vary by jurisdiction. Employers should have qualified counsel review their policy and procedures before implementation.